P3 Health Partners (PIII) had the highest return between April 1, 2023 and May 15, 2023 by a mid-cap US stock, returning 165.8%.
| ASSET | DATE | % RETURN |
|---|---|---|
P3 Health Partners (PIII) | 4/1/2023 - 5/15/2023 | 165.79% |
TG Therapeutics (TGTX) | 4/1/2023 - 5/15/2023 | 107.53% |
Soleno Therapeutics (SLNO) | 4/1/2023 - 5/15/2023 | 100.24% |
Immunitybio (IBRX) | 4/1/2023 - 5/15/2023 | 75% |
CleanSpark (CLSK) | 4/1/2023 - 5/15/2023 | 70.37% |
Ideaya Biosciences (IDYA) | 4/1/2023 - 5/15/2023 | 57.68% |
Nuvalent (NUVL) | 4/1/2023 - 5/15/2023 | 56.63% |
Legend Biotech (LEGN) | 4/1/2023 - 5/15/2023 | 55.15% |
Disc Medicine (IRON) | 4/1/2023 - 5/15/2023 | 50.87% |
StoneCo (STNE) | 4/1/2023 - 5/15/2023 | 48.42% |
PagSeguro Digital (PAGS) | 4/1/2023 - 5/15/2023 | 46.14% |
Crispr Therapeutics (CRSP) | 4/1/2023 - 5/15/2023 | 45.62% |
Green Brick Partners (GRBK) | 4/1/2023 - 5/15/2023 | 43.96% |
Amneal Pharmaceuticals, Inc Class A Common Stock (AMRX) | 4/1/2023 - 5/15/2023 | 43.26% |
Celsius (CELH) | 4/1/2023 - 5/15/2023 | 42.32% |
Inter & Co Inc Class A Common Shares (INTR) | 4/1/2023 - 5/15/2023 | 41.92% |
Arcellx (ACLX) | 4/1/2023 - 5/15/2023 | 41.81% |
Trevi Therapeutics (TRVI) | 4/1/2023 - 5/15/2023 | 41.18% |
Denali Therapeutics (DNLI) | 4/1/2023 - 5/15/2023 | 39.83% |
Crinetics Pharmaceuticals (CRNX) | 4/1/2023 - 5/15/2023 | 39.74% |
Vaxcyte (PCVX) | 4/1/2023 - 5/15/2023 | 34.9% |
Edgewise Therapeutics (EWTX) | 4/1/2023 - 5/15/2023 | 34.43% |
Xp (XP) | 4/1/2023 - 5/15/2023 | 34.04% |
Builders FirstSource (BLDR) | 4/1/2023 - 5/15/2023 | 33.35% |
Nanobiotix (NBTX) | 4/1/2023 - 5/15/2023 | 33.05% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.